$ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Healthcare
Sector
Biotechnology
Industry
Jerome Benedict Durso
CEO
59
Employees
$3.34
Current Price
$393.63M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 2 | 2 | $88,490.00 | 25,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 2 | 2 | $88,490.00 | 25,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 6 | 6 | $164,270.15 | 43,527 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | WEAVER GREGORY L Chief Financial Officer | Purchase | 5,000 | $3.54 | $17,700.00 | View Details |
| Mar 6, 2026 | Durso Jerome Benedict Director | Purchase | 20,000 | $3.54 | $70,790.00 | View Details |
| Jan 8, 2026 | Pisano Wayne Director | Purchase | 5,000 | $4.08 | $20,410.00 | View Details |
| Jan 5, 2026 | Sohn Catherine A. Director | Purchase | 500 | $4.24 | $2,117.55 | View Details |
| Dec 29, 2025 | Jorkasky Diane Director | Purchase | 527 | $3.80 | $2,002.60 | View Details |
| Dec 23, 2025 | GILL JOHN Director | Purchase | 12,500 | $4.10 | $51,250.00 | View Details |
| Dec 22, 2025 | Durso Jerome Benedict Director | Purchase | 12,500 | $4.13 | $51,568.75 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.25
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: